Bevasiranib sodium

Bevasiranib sodium is a small interfering RNA (siRNA) therapeutic agent designed to inhibit vascular endothelial growth factor (VEGF) expression. By silencing VEGF genes, it is applied in research models of choroidal neovascularization to study mechanisms and potential treatments for wet age-related macular degeneration, utilizing both in vitro and in vivo experimental approaches.